Analyst Rating Update on Biogen (BIIB)

Biogen (NASDAQ:BIIB) : Zacks Investment Research ranks Biogen (NASDAQ:BIIB) as 3, which is a Hold recommendation. 9 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 2 other analysts are mildly bullish on the stock and favor a Buy. A total of 6 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 17 research analysts is 1.79, which indicates as a Buy.

Biogen (NASDAQ:BIIB) : The consensus price target for Biogen (NASDAQ:BIIB) is $354.8 for the short term with a standard deviation of $50.9. The most optimist securities analyst among the 15 who monitor the stock believes that the stock can reach $450, however, the pessimist price target for the company is $268.

For the current week, the company shares have a recommendation consensus of Buy. Also, Equity Analysts at the Brokerage Firm, Citigroup, maintains their rating on the shares of Biogen (NASDAQ:BIIB). Citigroup has a Buy rating on the shares. As per the latest research report, the brokerage house lowers the price target to $295 per share from a prior target of $345. The rating by the firm was issued on June 8, 2016.

Biogen (NASDAQ:BIIB): stock turned positive on Tuesday. Though the stock opened at $225.68, the bulls momentum made the stock top out at $229.75 level for the day. The stock recorded a low of $225.68 and closed the trading day at $228.52, in the green by 1.75%. The total traded volume for the day was 2,115,685. The stock had closed at $224.6 in the previous days trading.

In an insider trading activity, Koppel Adam, officer (EVP, Strategy and Bus. Dev.) of Biogen Inc., unloaded 555 shares at an average price of $290 on June 6, 2016. The total amount of the transaction was worth $160,950, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Companys marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.